IHE / Eli Lilly Beats on Q3 Earnings: ETFs to Buy

Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug more_horizontal

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively more_horizontal

iShares U.S. Pharmaceuticals ETF invests almost 80 percent of its assets in its top 10 holdings, and 48.5 percent in just two companies: JNJ and LLY. more_horizontal

Investors seeking momentum may have iShares U.S. Pharmaceuticals ETF IHE on radar now. The fund recently hit a new 52-week high. more_horizontal

Wall Street wrapped up the last week with mixed performances. The pharma and energy sectors were the biggest winners last week. more_horizontal

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively more_horizontal

Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 more_horizontal

Launched on 05/01/2006, the iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed exchange traded fund designed to provide a broad exposure to more_horizontal